Arbutus Biopharma Corporation (ABUS) News
Filter ABUS News Items
ABUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ABUS News From Around the Web
Below are the latest news stories about ARBUTUS BIOPHARMA CORP that investors may wish to consider to help them evaluate ABUS as an investment opportunity.
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLDInitial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.In HBV003, 31% of participants with screening HBsAg level of ≤200 IU/mL had >1 log HBsAg reductions. VTP-300 was generally well-tolerated in both trials. OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced the presentation of data from two HBV clinical trials at Th |
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 show early signs of immune activation WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatiti |
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call TranscriptArbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript November 7, 2023 Arbutus Biopharma Corporation reports earnings inline with expectations. Reported EPS is $-0.12 EPS, expectations were $-0.12. Operator: Good day, and thank you for standing by. Welcome to the Arbutus Third Quarter Corporate and Financial Update Conference Call. [Operator Instructions] Please be advised that […] |
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This WeekCelebrations may be in order for Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders, with the analysts... |
Arbutus to Present at Jefferies London Healthcare ConferenceWARMINSTER, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following investor conference: Jefferies London Healthcare Conference: Formal presentation on Wednesday, |
Q3 2023 Arbutus Biopharma Corp Earnings CallQ3 2023 Arbutus Biopharma Corp Earnings Call |
Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial ResultsCompany continues clinical trials and reduces workforce by 24% amidst pipeline optimization |
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateMultiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV antigen-specific immunotherapy Dosing continues in two Phase 2a combination clinical trials with imdusiran and in a Phase 1a/1b clinical trial with AB-101, our oral PD-L1 checkpoint inhibitor Reducing workforce by 24% as a result of recent pipeline optimization Cash runway extended into first quarter 2026 Confe |
Arbutus Announces CEO, William Collier, to Retire December 31, 2023Michael J. McElhaugh, Arbutus Co-founder and COO, to Serve as Interim CEO WARMINSTER, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, today announced that William Collier will retire from his position as the Company’s President and Chief Executive Officer, and as a mem |
12 Best Micro Cap Stocks To Invest InIn this piece, we will take a look at the 12 best micro cap stocks to invest in. To skip our introduction to micro cap investing, some benefits, and potential risks, you can skip ahead to 5 Best Micro Cap Stocks To Invest In. Depending on who you ask, it can be argued that the […] |